Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

Marked Improvement in Four Regions of Body Consistent with Overall PASI

Response in REMICADE-Treated Patients

SAN ANTONIO, Feb. 4 /PRNewswire/ -- Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) achieved a consistently high level of skin clearance in each of the four body regions (head, trunk, lower and upper extremities) as measured by the Psoriasis Area Severity Index (PASI). At week 10 of the analysis, which included nearly 1,500 subjects, 71 percent of patients receiving REMICADE 3 mg/kg and 79 percent of patients receiving REMICADE 5 mg/kg achieved a PASI 75, or at least a 75 percent improvement in the chronic inflammatory condition, compared with three percent of patients receiving placebo (both P < 0.001). Additionally, 39 percent and 52 percent of patients receiving REMICADE 3 mg/kg and 5 mg/kg, respectively, achieved a PASI 90, or nearly complete skin clearance, versus one percent of patients receiving placebo (both P < 0.001). Investigators reported these findings at the 66th Annual Meeting of the American Academy of Dermatology.

In September 2006, the U.S. Food and Drug Administration (FDA) approved REMICADE (5 mg/kg) for the treatment of chronic severe plaque psoriasis. Following an initial three infusion treatments (induction regimen), REMICADE is given once every eight weeks, or as few as six times a year.

"This analysis shows that treatment with REMICADE resulted in a consistently high level of clinical response in each quadrant of the body evaluated by PASI, and the results were consistent with patients' overall psoriasis improvement," said Alan Menter, MD, dermatologist, Baylor Research Institute, Dallas, and lead study investigator. "REMICADE remains an important advancement and biologic treatment option for a broad spectrum of patients with severe psoriasis."

According to f
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Concord ... "Company") (NYSE: CCM ), a leading specialty ... largest network of radiotherapy and diagnostic imaging centers ... the signing of a purchase agreement under which ... owned subsidiary of the Company, agreed to acquire ...
(Date:3/26/2015)... ON , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics ... pharmaceutical company with a focus on Omega-3 therapies for ... 25, 2015 it issued 763,752 common shares of the ... of interest for the period of December 5 th ... its outstanding Convertible Notes that is due on or ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... announced today that it has updated coverage on ... Company")and maintains its twelve month target price of $6.50. Ross ... Company, Opexa,s lead clinical candidate Tovaxin®, an autologous cellular immunotherapy ... to advance into a pivotal Phase 3 clinical study in ...
... Electronics, a San Jose, California based cable and harness assembly ... in San Jose, CA.  The company will add another 12,500 ... stay ahead of our customers, needs and these new initiatives ... that," says VP of Operations, Ruben Macias. The plant expansion ...
Cached Medicine Technology:Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50 2DC Electronics Expands Facilities to Increase Capacity 2
(Date:3/29/2015)... 2015 The culmination of one of the ... the Final Four invades Lucas Oil Stadium in ... one filled with excitement, buzzer-beaters, and of course, upsets. Throughout ... have been made, and future professional products have been seen. ... the four teams that advanced through their regional bracket with ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 Final ... new transition from Pixel Film Studios, entitled TranSports. ... made exclusively for Final Cut Pro X,” said Christiana ... users the tools needed to effortlessly transition using this ... TranSports, a new and uniquely styled transition pack for ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body care ... natural sunscreen. They are offering the sunscreen in both ... with a bonus lip balm sunscreen. , The new products ... Click to see the natural sunscreen on Amazon . , ... with non-nano zinc oxide and provides broad-based protection against UVA ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as ... at the latest and coolest applications on the market ... of NewsWatch and technology expert, conducted the app review ... endless runner game with knights, nature, and peasants. ... 2009, according to Eurogamer. The popularity of these games ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2
... Baiganwadi slum at Govandi is becoming a source of fright ... polio cases have been reported in 2 weeks from this ... contaminated with dengue transmitting Aedes aegypti mosquitoes and malarial parasites. ... has taken 3 lives in this area; 2 in September ...
... have arrived in Bahrain to receive urgently needed medical treatment.// ... coming days as part of an agreement with the World ... response to a call to help fund treatment for seriously ... is the head of the newly established Organisation for Culturing ...
... labourers coming home for the festive season comprise most of ... afflicted with the mosquito-borne virus so far.// ,State ... in the state. ,Most of the suspected dengue ... places like Delhi, Rajasthan, Haryana and Uttar Pradesh for the ...
... recorded by an unsteadily held camera, one can feel nauseous. ... almost continuous shaky video stream from our eyes which is ... our bodies which is in constant motion at any given ... for Biological Studies have found that the brain not only ...
... backlogs of patients for important surgeries has alerted ... the issue. According to the complaint, operations ... been put on the back burner, with patients ... of evidence to support these complaints has spurred ...
... three-year, $728,000 grant from the US Department of Health ... School of Nursing has established a new palliative care ... Palliative care nursing provides care for patients with serious ... first college or university in New England to offer ...
Cached Medicine News:Health News:A slum in Mumbai – breeding ground for disease 2Health News:Migrant Bihar Labourers Bring Dengue Home 2Health News:Perception Stabilized – Thanks to Your Brains 2Health News:Perception Stabilized – Thanks to Your Brains 3Health News:College Launches Palliative Care Nursing Program 2
... Includes base with vacuum stage, porous vacuum ... gaskets, lid, instructions. The Model 785 vacuum ... from an agarose gel onto a nylon membrane. ... transfer, the nucleic acid samples can be separated ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
Inquire...
... Blotting System. Designed for Western, ... up to three gels with dimensions ... Includes and internal cooling base ... cover with attached power leads. ...
Medicine Products: